Mynd life sciences announces shares for debt transaction

Vancouver, british columbia--(newsfile corp. - february 11, 2025) - mynd life sciences inc. (cse: mynd) (otc pink: myndf) ("mynd" or the "company") a clinical-stage life sciences company committed to the development and commercialization of drug therapies and diagnostics to improve the monitoring and treatment of depression, today announced that it has entered into shares for debt agreements (the "agreements"), to satisfy an aggregate of $2,273,062.30 of the company's outstanding debt (the "indebtedness") related to loan, fees including all principal, accrued and unpaid interest, costs payments outstanding. an aggregate of 22,730,623 common shares in the capital of the company (the "shares") at a deemed price of $0.10 per share are proposed to be issued to the creditors.
MYND Ratings Summary
MYND Quant Ranking